Blepharitis
Definition
Inflammation of the eyelid margins, classified as anterior (affecting the eyelash follicles and associated glands) or posterior (affecting the meibomian glands), and further categorized by etiology including staphylococcal, seborrheic, and mixed forms.
Clinical Snapshot
Blepharitis is one of the most common conditions encountered in eye care, encompassing a spectrum of lid margin inflammatory disorders. Anterior blepharitis affects the lash follicles and anterior lid margin; posterior blepharitis (meibomian gland dysfunction) affects the posterior lid margin and meibomian gland orifices. Most patients have mixed anterior and posterior disease. Blepharitis is chronic and recurrent — management focuses on control rather than cure.
Epidemiology
Blepharitis is among the most prevalent ocular conditions, affecting an estimated 37–47% of patients presenting to eye care providers. Prevalence increases with age. Anterior blepharitis is more common in younger patients; posterior blepharitis (MGD) predominates in older adults.
Pathophysiology
Anterior blepharitis results from colonization of the lash follicles by Staphylococcus aureus and S. epidermidis, which produce exotoxins and lipases that trigger lid margin inflammation. Seborrheic blepharitis is associated with Malassezia overgrowth and sebaceous gland dysfunction. Posterior blepharitis (MGD) involves ductal obstruction and meibum stasis. All forms share a common downstream pathway of lid margin inflammation, tear film destabilization, and ocular surface disease.
Risk Factors
- Advanced age
- Seborrheic dermatitis and rosacea
- Demodex infestation
- Contact lens wear
- Immunocompromised states
- Poor lid hygiene
Clinical Presentation
Patients report burning, itching, foreign body sensation, and crusting at the lash base — typically worse upon awakening. Anterior blepharitis presents with collarettes (fibrinous scales around lash bases), lash loss (madarosis), and misdirected lashes (trichiasis). Posterior blepharitis presents with lid margin telangiectasia, plugged meibomian gland orifices, and turbid meibum. Conjunctival injection, papillary reaction, and superficial punctate keratopathy are common associated findings.
Diagnostic Pearls
- Collarettes at the lash base are pathognomonic for Demodex blepharitis — distinguish from the hard scales of staphylococcal blepharitis.
- Lid margin telangiectasia and irregular posterior lid margin architecture indicate posterior blepharitis/MGD.
- Madarosis (lash loss) in a focal pattern should raise concern for sebaceous cell carcinoma — biopsy if in doubt.
- Assess meibomian gland expression quality at every blepharitis visit — it guides therapy and tracks response.
Differential Diagnosis
- Demodex blepharitis
- Ocular rosacea
- Sebaceous cell carcinoma (masquerade syndrome)
- Allergic contact dermatitis of the lids
- Pediculosis (Phthirus pubis infestation)
- Psoriatic lid disease
Evidence-Based Management
Lid hygiene is the cornerstone of blepharitis management. Warm compresses soften crusts and liquefy meibum; lid scrubs with dilute baby shampoo or commercial lid cleansers (hypochlorous acid, surfactant wipes) remove debris and reduce bacterial colonization. Topical azithromycin (AzaSite®) provides antibiotic and anti-inflammatory benefit at the lid margin. Short-course topical corticosteroids (TobraDex®, FML®) address acute inflammatory flares. Oral doxycycline is appropriate for moderate-to-severe posterior blepharitis with rosacea. Demodex blepharitis requires targeted therapy with lotilaner (Xdemvy®) or tea tree oil-based products.
Monitoring & Follow-Up
Blepharitis is chronic — patients require ongoing management and periodic reassessment. Follow-up at 4–8 weeks after initiating therapy, then every 3–6 months for stable disease. Monitor for complications including chalazia, corneal pannus, and marginal keratitis.
Clinical Pearls
- Blepharitis is managed, not cured — patient education about the chronic nature of the condition is essential for long-term adherence.
- Demodex should be actively screened in treatment-resistant blepharitis — cylindrical dandruff is the pathognomonic sign.
- Focal madarosis or a unilateral, treatment-resistant lid margin lesion should prompt biopsy to exclude sebaceous cell carcinoma.
- Lid hygiene compliance is the most common barrier to treatment success — simplify the regimen and demonstrate technique in office.
Related Therapeutics — Clinician's Companion
- Lid Margin & Demodex — Xdemvy®, AzaSite®, Lid Hygiene (Clinician's Companion)
- Anti-inflammatory Rescue — TobraDex®, FML® (Clinician's Companion)
- Oral Therapeutics — Doxycycline (Clinician's Companion)
Key References
- 1.Lindsley K, et al. Interventions for chronic blepharitis. Cochrane Database Syst Rev. 2012.
- 2.American Academy of Ophthalmology Preferred Practice Pattern: Blepharitis (current edition).
- 3.Kabat AG, Sowka JW. Blepharitis: A Clinical Overview. Optometry. 2009.
This entry is an educational reference designed to support clinical reasoning and awareness. It does not constitute medical advice, establish a standard of care, or replace individualized patient assessment. Clinicians should consult current guidelines and applicable clinical resources when making patient care decisions.